[go: up one dir, main page]

MX2013004710A - Antibodies for the treatment of hiv. - Google Patents

Antibodies for the treatment of hiv.

Info

Publication number
MX2013004710A
MX2013004710A MX2013004710A MX2013004710A MX2013004710A MX 2013004710 A MX2013004710 A MX 2013004710A MX 2013004710 A MX2013004710 A MX 2013004710A MX 2013004710 A MX2013004710 A MX 2013004710A MX 2013004710 A MX2013004710 A MX 2013004710A
Authority
MX
Mexico
Prior art keywords
antibodies
cxcr4
treatment
hiv
relates
Prior art date
Application number
MX2013004710A
Other languages
Spanish (es)
Inventor
Chistine Klinguer-Hamour
Original Assignee
Pf Medicament
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US12/913,300 external-priority patent/US9090686B2/en
Application filed by Pf Medicament filed Critical Pf Medicament
Publication of MX2013004710A publication Critical patent/MX2013004710A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • AIDS & HIV (AREA)
  • Biomedical Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

The present invention relates to isolated antibodies, or the derivatives or antigen binding fragments of same, capable of binding to CXCR4 but also of inducing conformational change of the CXCR4 homodimers and able to inhibit HIV-1 primary isolate replication in PBMC. More particularly, the present invention relates to the 515H7 and 301 aE5 monoclonal antibodies, specific to the CXCR4 protein, as well as their use for the treatment of HIV infection. Pharmaceutical compositions comprising such antibodies and a process for the selection of such antibodies are also covered.
MX2013004710A 2010-10-27 2011-10-27 Antibodies for the treatment of hiv. MX2013004710A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12/913,300 US9090686B2 (en) 2009-04-29 2010-10-27 Antibodies for the treatment of HIV
PCT/EP2011/068905 WO2012055980A1 (en) 2010-10-27 2011-10-27 Antibodies for the treatment of hiv

Publications (1)

Publication Number Publication Date
MX2013004710A true MX2013004710A (en) 2013-08-29

Family

ID=44913256

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013004710A MX2013004710A (en) 2010-10-27 2011-10-27 Antibodies for the treatment of hiv.

Country Status (10)

Country Link
EP (1) EP2632953A1 (en)
JP (1) JP2014504147A (en)
KR (1) KR20140009174A (en)
CN (1) CN103180342A (en)
AU (1) AU2011322508A1 (en)
CA (1) CA2814908A1 (en)
MX (1) MX2013004710A (en)
RU (1) RU2013122770A (en)
WO (1) WO2012055980A1 (en)
ZA (1) ZA201302639B (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014224049B2 (en) * 2013-02-28 2018-11-29 Therabiol, Inc. HIV antigens and antibodies
AU2014359085B2 (en) * 2013-12-08 2017-11-02 Peptcell Limited HIV antigens and antibodies and compositions, methods and uses thereof
EP3471754A1 (en) 2016-06-20 2019-04-24 Kymab Limited Anti-pd-l1 antibodies

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
GB9014932D0 (en) 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
JPH05244982A (en) 1991-12-06 1993-09-24 Sumitomo Chem Co Ltd Humanized b-b10
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US20050002939A1 (en) * 2002-12-23 2005-01-06 Albert Zlotnik Tumor killing/tumor regression using CXCR4 antagonists
JP2011520885A (en) * 2008-05-14 2011-07-21 イーライ リリー アンド カンパニー Anti-CXCR4 antibody
EP2172485A1 (en) * 2008-10-01 2010-04-07 Pierre Fabre Medicament Novel anti CXCR4 antibodies and their use for the treatment of cancer
JP2012158521A (en) * 2009-04-17 2012-08-23 Kureha Corp Preparation for external use
EP2246364A1 (en) * 2009-04-29 2010-11-03 Pierre Fabre Médicament Anti CXCR4 antibodies for the treatment of HIV
EP2371863A1 (en) * 2010-03-30 2011-10-05 Pierre Fabre Médicament Humanized anti CXCR4 antibodies for the treatment of cancer

Also Published As

Publication number Publication date
CA2814908A1 (en) 2012-05-03
AU2011322508A1 (en) 2013-05-02
WO2012055980A1 (en) 2012-05-03
KR20140009174A (en) 2014-01-22
JP2014504147A (en) 2014-02-20
ZA201302639B (en) 2013-11-27
EP2632953A1 (en) 2013-09-04
CN103180342A (en) 2013-06-26
RU2013122770A (en) 2014-12-10

Similar Documents

Publication Publication Date Title
MY155400A (en) Anti cxcr4 antibodies for the treatment of hiv
UA102867C2 (en) Anti cxcr4 antibodies and their use for the treatment of cancer
NZ754051A (en) Novel antibodies and uses thereof
ZA202001564B (en) Anti- folate receptor alpha antibody conjugates and their uses
TN2012000466A1 (en) Humanized anti cxcr4 antibodies for the treatment of cancer
BRPI1008145B8 (en) Bispecific antigen binding protein, method for preparing a bispecific antigen binding protein, transgenic microorganism, pharmaceutical composition and use of the bispecific antigen binding protein
CO6640289A2 (en) Compositions of anti-nerve growth factor antibodies (ngf)
MX2022004072A (en) Factor xi antibodies and methods of use.
EP4338754A3 (en) Antigen binding proteins
MY175687A (en) Composition comprising two antibodies engineered to have reduced and increased effector function
MX350200B (en) Human antibodies and antibody-drug conjugates against cd74.
TN2011000528A1 (en) Compositions and methods for antibodies targeting complement protein c3b
PE20241623A1 (en) OPTIMIZATION OF ANTIBODIES THAT BIND TO LYMPHOCYTE ACTIVATION GENE 3 (LAG-3) AND THEIR USES
MX2010003574A (en) Il-23 antibodies.
MX354481B (en) DKK1 ANTIBODIES and METHODS OF USE.
EP4414376A3 (en) Novel depsipeptide and uses thereof
MX2012006430A (en) Combination preparations comprising a cytokine antagonist and corticosteroid.
WO2011116212A3 (en) Bone morphogenetic protein receptor binding agents and methods of their use
MX2021005085A (en) Antibody formulation.
WO2012047267A3 (en) Polyvalent immunogen
EA201300138A1 (en) PHARMACEUTICAL COMPOSITION AND METHOD OF INHIBITING PRODUCTS OR ENHANCEMENT OF ELIMINATION OF PROTEIN P24
MX2013004710A (en) Antibodies for the treatment of hiv.
MX348459B (en) QUICK SELECTION METHOD FOR HIV VARIANTS GP-120.
MX2013003168A (en) Anti-ephrin-b2 antibody and use thereof.
EP4061416A4 (en) Powassan viral antigens and related compositions, and uses thereof to vaccinate and treat patients